在患有牙周炎和慢性阻塞性肺病的患者中IL-33
Mei Lin1, Xiao-Li Gao1, Wei Li1
1Department of Stomatology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Human immunology
|May 16, 2024
概括
较低的血清中介素-33 (IL-33) 水平与牙周炎和慢性阻塞性肺病 (COPD) 的风险和严重程度增加有关. 这表明IL-33在这些疾病的共享炎症途径中发挥作用.
科学领域:
- 口腔健康研究 口腔健康研究
- 肺部医学 肺部医学
- 免疫学 免疫学 免疫学
背景情况:
- 牙周炎和慢性阻塞性肺病 (COPD) 具有共同的炎症途径.
- 介素-33 (IL-33) 参与了这两种疾病的炎症机制.
研究的目的:
- 研究血清IL-33水平与牙周炎和COPD的发生和严重程度之间的关联.
- 探索IL-33在牙周炎和COPD之间的病理生理联系中的作用.
主要方法:
- 161名参与者被分为四组:健康,仅患有牙周炎,仅患有COPD,以及结合性牙周炎和COPD.
- 血清IL-33水平使用酶相关免疫吸收试验 (ELISA) 量化.
- 与IL-33水平相关的临床因素,疾病风险和严重程度被分析.
主要成果:
- 与健康对照组相比,所有患者组的血清IL-33水平显著降低.
- 在患有牙周炎和COPD的患者中观察到更低IL-33水平的趋势.
- 较低的IL-33水平与牙周炎和COPD的严重程度和风险相反相关.
结论:
- 该研究发现血清IL-33水平与牙周炎和COPD的存在/严重程度之间存在显著的反向关联.
- 研究结果表明,IL-33参与了连接牙周炎和COPD的炎症机制.
- 这项研究为COPD的新型预防和治疗策略提供了基础.
相关概念视频
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K
01:22Chronic Obstructive Pulmonary Disease
1.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.2K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
01:17Drugs Used in Lower Respiratory Disorders: Overview
424
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
424